Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Passiglia

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Translational Lung Cancer Research|April 11, 2022
Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancerHaitao Tao, Fangfang Li, Dongxiao Wu, et al.
Scientific Reports|November 20, 2018
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Expert Opinion on Investigational Drugs|February 17, 2016
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancerFrancesco Passiglia, Rafael Caparica, Elisa Giovannetti, et al.
Cancer|March 11, 2023
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapyPaolo Bironzo, Massimiliano Cani, Francesca Jacobs, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2021
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC eraFrancesco Passiglia, Gianmarco Leone, Emanuela Olmetto, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
Expert Review of Anticancer Therapy|December 16, 2014
Cancer and the microbiome: potential applications as new tumor biomarkerKhan Shahanavaj, Ignacio Gil-Bazo, Marta Castiglia, et al.
Oncotarget|August 31, 2015
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, et al.
Critical Reviews in Oncology/Hematology|September 18, 2013
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspectsGiuseppe Bronte, Christian Rolfo, Elisa Giovannetti, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Translational Lung Cancer Research|April 11, 2022
Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancerHaitao Tao, Fangfang Li, Dongxiao Wu, et al.
Scientific Reports|November 20, 2018
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Expert Opinion on Investigational Drugs|February 17, 2016
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancerFrancesco Passiglia, Rafael Caparica, Elisa Giovannetti, et al.
Cancer|March 11, 2023
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapyPaolo Bironzo, Massimiliano Cani, Francesca Jacobs, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2021
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC eraFrancesco Passiglia, Gianmarco Leone, Emanuela Olmetto, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
Expert Review of Anticancer Therapy|December 16, 2014
Cancer and the microbiome: potential applications as new tumor biomarkerKhan Shahanavaj, Ignacio Gil-Bazo, Marta Castiglia, et al.
Oncotarget|August 31, 2015
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, et al.
Critical Reviews in Oncology/Hematology|September 18, 2013
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspectsGiuseppe Bronte, Christian Rolfo, Elisa Giovannetti, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Pageof 13